Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression
This commentary (2024) provides an evidence-informed assessment of psychedelic research for treating depression. It discusses the shift in media reporting from overstating the risks to overly positive hype and emphasizes the need for clear science communication to set public expectations and inform policy decisions accurately.
Authors
- Milan Scheidegger
- Sandeep Nayak
- David Yaden
Published
Abstract
Rationale
Psychedelic research re-emerged from a period of suppression into the so-called psychedelic renaissance. In parallel, most media reporting has shifted from the overstatement of the risks of psychedelics to overly positive hype. As the empirical evidence is more equivocal than frequently portrayed, the conclusions about the effectiveness of psychedelics should be considered preliminary. Poor science communication about psychedelics’ therapeutic potential may lead potential participants or patients to feel misled and policy decisions to be misinformed. An evidence-informed characterization of their risks and benefits is needed.
Objectives
This article assesses the state of psychedelic research for treating depression and the effect sizes of psychedelics on therapeutic outcomes, the risk of bias, and the prevalence of adverse effects. We review research on the risks and benefits of psychedelics and discuss how the following depression treatments have shown decreasing effect sizes over time: (1) cognitive behavioral therapy, (2) mindfulness interventions, (3) selective serotonin reuptake inhibitors, and (4) ketamine. We speculate that a similar trend may occur for psychedelic treatments. Results and conclusions: It is likely that larger and better-controlled psychedelic trials will demonstrate smaller effect sizes that are more comparable to other conventional and emerging treatments for mood disorders. Clear science communication is critical for setting public expectations and psychedelic policy. With this evidence-based assessment, we aim to cut through the misinformation about the benefits, risks, and future prospects of psychedelic treatments.
Research Summary of 'Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression'
Introduction
Public and scientific interest in the therapeutic potential of psychedelics has surged alongside a revival of clinical research after decades of suppression. Meling and colleagues frame this resurgence against a backdrop of shifting media representation: decades of alarmist messaging about harms have been partially replaced by enthusiastic coverage emphasising benefits. The authors argue that the empirical evidence remains preliminary and more equivocal than often portrayed, and that inflated expectations (or “hype”) can produce expectancy effects, selection bias, and misinformed policy decisions. This narrative review sets out to characterise the risks and benefits of psychedelic treatments for depression by summarising reported effect sizes, the prevalence of adverse events, and the risk of bias in published trials. The study compares psychedelic findings to historical trends in four other depression treatments—cognitive behavioural therapy (CBT), mindfulness interventions, selective serotonin reuptake inhibitors (SSRIs), and ketamine—to examine whether psychedelics might follow the same pattern of declining effect sizes as studies grow larger and more rigorous. The authors also aim to identify methodological shortcomings (for example, blinding failures and publication bias) and to offer recommendations for future trials and science communication.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Topics
- Authors
- APA Citation
Meling, D., Ehrenkranz, R., Nayak, S. M., Aicher, H. D., Funk, X., van Elk, M., Graziosi, M., Bauer, P. R., Scheidegger, M., & Yaden, D. B. (2024). Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression. Psychoactives, 3(2), 215-234. https://doi.org/10.3390/psychoactives3020014
References (34)
Papers cited by this study that are also in Blossom
Goldberg, S. B., Shechet, B., Nicholas, C. R. et al. · Psychological Medicine (2020)
Luoma, J. B., Chwyl, C., Bathje, G. J. et al. · Journal of Psychoactive Drugs (2020)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)
van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)
Nichols, D. E. · Pharmacological Reviews (2016)
Anderson, B. T., Danforth, A. L., Daroff, R. et al. · EClinicalMedicine (2020)
Hadar, A., David, J., Shalit, N. et al. · Journal of Psychoactive Drugs (2022)
Lawrence, D. W., Sharma, B., Griffiths, R. R. et al. · Journal of Psychoactive Drugs (2021)
Show all 34 referencesShow fewer
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Raison, C. L., Sanacora, G., Woolley, J. D. et al. · JAMA (2023)
Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)
Goodwin, G. M. · Journal of Affective Disorders (2023)
Schindowski, E. M., Jungwirth, J., Schuldt, A. et al. · EClinicalMedicine (2023)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Neil, J. C., Nutt, D. J. · Journal of Psychopharmacology (2022)
Hartogsohn, I. · Drug Science Policy and Law (2017)
Haikazian, S., Chen-Li, D., Johnson, D. et al. · Psychiatry Research (2023)
Kopra, E., Cleare, A. J., Rucker, J. et al. · Journal of Affective Disorders (2022)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Breeksema, J. J., Kuin, B. W., Kamphuis, J. et al. · Journal of Psychopharmacology (2022)
Hinkle, J. T., Graziosi, M., Nayak, S. et al. · JAMA Psychiatry (2024)
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)
Johnson, M. W., Gründer, G., Betzler, F. et al. · Current Addiction Reports (2021)
Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)
Palhano-Fontes, F., Barreto, D., Onias, H. et al. · Psychological Medicine (2018)
Osório, F. L., Sanches, R. F., Macedo, L. et al. · brazilian Journal of Psychiatry (2015)
Fond, G., Loundou, A., Macgregor, A. et al. · Psychopharmacology (2014)
Coyle, C. M., Laws, K. R. · Human Psychopharmacology (2015)
Nikolin, S., Rodgers, A., Schwaab, A. et al. · EClinicalMedicine (2023)
Van Elk, M., Fried, E. I. · Therapeutic Advances in Psychopharmacology (2023)
Cited By (2)
Papers in Blossom that reference this study
Evans, J., Aixalà, M., Anderson, B. T. et al. · Psychiatric Research & Clinical Practice (2025)
Meling, D., Egger, K., Aicher, H. D. et al. · Journal of Psychopharmacology (2024)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.